drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Daratumumab; a fully human IgG1κ monoclonal antibody against CD38 that mediates CDC, ADCC, ADCP, induces apoptosis, and modulates CD38 NADase activity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Daratumumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Daratumumab is a fully human IgG1κ monoclonal antibody targeting CD38 on plasma cells; it depletes CD38+ cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), can induce apoptosis upon crosslinking, and modulates CD38 ectoenzyme (NADase) activity, disrupting CD38/NAD+ signaling.
drug_name
Darzalex (daratumumab)
nct_id_drug_ref
NCT05974969